Moule S K, Welsh G I, Edgell N J, Foulstone E J, Proud C G, Denton R M
Department of Biochemistry, School of Medical Sciences, University of Bristol, Bristol, BS8 1TD, United Kingdom.
J Biol Chem. 1997 Mar 21;272(12):7713-9. doi: 10.1074/jbc.272.12.7713.
Previous studies using L6 myotubes have suggested that glycogen synthase kinase-3 (GSK-3) is phosphorylated and inactivated in response to insulin by protein kinase B (PKB, also known as Akt or RAC) (Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovic, M., and Hemmings, B. A. (1995) Nature 378, 785-789). In the present study, marked increases in the activity of PKB have been shown to occur in insulin-treated rat epididymal fat cells with a time course compatible with the observed decrease in GSK-3 activity. Isoproterenol, acting primarily through beta3-adrenoreceptors, was found to decrease GSK-3 activity to a similar extent (approximately 50%) to insulin. However, unlike the effect of insulin, the inhibition of GSK by isoproterenol was not found to be sensitive to inhibition by the phosphatidylinositol 3'-kinase inhibitors, wortmannin or LY 294002. The change in GSK-3 activity brought about by isoproterenol could not be mimicked by the addition of permeant cyclic AMP analogues or forskolin to the cells, although at the concentrations used, these agents were able to stimulate lipolysis. Isoproterenol, but again not the cyclic AMP analogues, was found to increase the activity of PKB, although to a lesser extent than insulin. While wortmannin abolished the stimulation of PKB activity by insulin, it was without effect on the activation seen in response to isoproterenol. The activation of PKB by isoproterenol was not accompanied by any detectable change in the electrophoretic mobility of the protein on SDS-polyacrylamide gel electrophoresis. It would therefore appear that distinct mechanisms exist for the stimulation of PKB by insulin and isoproterenol in rat fat cells.
此前使用L6肌管进行的研究表明,糖原合酶激酶-3(GSK-3)会被蛋白激酶B(PKB,也称为Akt或RAC)磷酸化并失活,以响应胰岛素(克罗斯,D.A.E.,阿莱西,D.R.,科恩,P.,安杰尔科维奇,M.,和赫明斯,B.A.(1995年)《自然》378卷,785 - 789页)。在本研究中,已表明在胰岛素处理的大鼠附睾脂肪细胞中,PKB活性显著增加,其时间进程与观察到的GSK-3活性降低相吻合。异丙肾上腺素主要通过β3 - 肾上腺素能受体起作用,被发现可将GSK-3活性降低到与胰岛素相似的程度(约50%)。然而,与胰岛素的作用不同,未发现异丙肾上腺素对GSK的抑制作用对磷脂酰肌醇3'-激酶抑制剂渥曼青霉素或LY 294002的抑制敏感。尽管在所用浓度下这些试剂能够刺激脂解,但向细胞中添加渗透性环磷酸腺苷类似物或福斯可林并不能模拟异丙肾上腺素引起的GSK-3活性变化。异丙肾上腺素,但同样不是环磷酸腺苷类似物,被发现可增加PKB活性,尽管程度低于胰岛素。虽然渥曼青霉素消除了胰岛素对PKB活性的刺激,但对异丙肾上腺素引起的激活没有影响。异丙肾上腺素对PKB的激活在SDS - 聚丙烯酰胺凝胶电泳上未伴随该蛋白电泳迁移率的任何可检测变化。因此,在大鼠脂肪细胞中,胰岛素和异丙肾上腺素刺激PKB似乎存在不同的机制。